Adamis Pharmaceuticals Provides Update on Clinical Study Evaluating Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Corporation

DSMB met to evaluate interim clinical and safety data and authorizes the continuation of the phase 2/3 study

SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3 clinical trial investigating the use of Tempol for the treatment of COVID- 19, met to assess the clinical and safety data from the first planned interim analysis. Following their evaluation, the DSMB recommended that the study continue without modification.

“We continue to be pleased with the conduct of the trial and look forward to the next DSMB meeting currently scheduled for May,” said Dr. Dennis J. Carlo, President and CEO of Adamis Pharmaceuticals.

About the Phase 2/3 Clinical Trial

Additional information about the trial is available at using the identifier NCT04729595.

Adamis has licensed exclusive worldwide rights to certain patents, patent applications and related know-how relating to Tempol for certain licensed areas, including the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza and COVID-19, and for radiation reduction. induced dermatitis in patients undergoing cancer treatment.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on the development and commercialization of products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory diseases. The company’s SYMJEPI® (epinephrine) Injectable products are FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company’s ZIMHI™ (naloxone) injectable product is approved for the treatment of opioid overdose ( Tempol is being developed for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway. For more information about Adamis Pharmaceuticals, please visit and follow us on Twitter and LinkedIn.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipations, intentions, contingencies, objectives, targets or future developments and /or are not otherwise statements of historical fact. These statements relate to future events or future operating results, including, but not limited to, the following statements: statements regarding the Company’s Phase 2/3 clinical trial for Tempol; statements regarding the activities and process of the DSMB and the timing and results of this process; the Company’s beliefs regarding the mechanisms of action, safety and efficacy of Tempol and that Tempol fulfills an unmet medical need; the timing, progress or results of the Company’s Phase 2/3 clinical trial for Tempol or other studies or trials relating to Tempol; the opinions and beliefs of any third parties identified in this press release regarding the potential of Tempol as a treatment for COVID-19 and the results of previous studies of Tempol; the Company’s ability to commercialize the product candidates described in this press release, either itself or through commercialization partners; the Company’s beliefs regarding the benefits, applicability and extent of intellectual property rights and protection afforded by patents and patent applications it owns or has licensed, including those relating to Tempol ; and other statements regarding the future operations and activities of the Company. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to differ materially from the results anticipated by such forward-looking statements. There is no guarantee regarding the time DSMB will take to conduct or complete the interim analyzes and reviews described in this press release, regarding the results or outcome of such analysis, or regarding any decisions the Company will make after to have received information concerning this analysis. There can be no guarantees regarding the timing, progress or results of any trials or studies relating to Tempol, or that Tempol will be found to be safe and effective in the treatment of COVID-19 or any other indication. In addition, as previously reported, the Company and its subsidiary US Compounding Inc. have each received a subpoena from the US Attorney’s Office for the Southern District of New York issued in connection with a criminal investigation. Accordingly, all forward-looking statements are subject to the outcome of this investigation and any other governmental investigation or proceeding. We cannot assess the impact of each factor on our business or the extent to which any one factor, or combination of factors, could cause actual results to differ materially from those contained in the forward-looking statements. You should not place undue reliance on forward-looking statements. Further, any forward-looking statement speaks only as of the date the statement is made, and except as required by applicable law, we undertake no obligation to update or publicly release the results of any revisions to such statements. forward-looking statements or to reflect events or circumstances occurring after the date of this press release. Certain of these risks and additional risks, uncertainties and other factors are described in greater detail in Adamis’s filings from time to time with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and the subsequent deposits. with the SEC, which Adamis urges you to read and consider, all available free of charge on the SEC’s website at


Adamis Investor Relations
Robert Uhl
General manager
ICR Westwicke
[email protected]

Comments are closed.